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In embryonic stem cells, removal of oxidatively damaged proteins is triggered upon the first signs of cell fate
specification but the underlying mechanism is not known. Here, we report that this phase of differentiation
encompasses an unexpected induction of genes encoding the proteasome activator PA28ab (11S), subunits
of the immunoproteasome (20Si), and the 20Si regulator TNFa. This induction is accompanied by assembly
of mature PA28-20S(i) proteasomes and elevated proteasome activity. Inhibiting accumulation of PA28a
using miRNA counteracted the removal of damaged proteins demonstrating that PA28ab has a hitherto
unidentified role required for resetting the levels of protein damage at the transition from self-renewal to cell
differentiation.
P
rotein carbonylation, resulting from ametal catalysed oxidation involving hydrogen peroxide (H2O2) as the
oxidant1,2, has become one of the most commonly used biomarkers of severe oxidative damage to proteins.
Protein carbonylation increases during aging and this oxidative modification has been linked to the
development of age-related neurological disorders and an age-dependent decline in the activity of many proteins,
including the proteasome1,3–6. Therefore, it has been hypothesized that the protein carbonyl load of young
individuals must be sufficiently low to avoid detrimental effects on fitness1,3, a notion which is true for the
progeny of many aging species1,7,8. However, undifferentiated mouse embryonic stem (ES) cells were found to
contain relatively high levels of carbonylated proteins and advanced glycation end products but upon differenti-
ation such damage was efficiently eliminated9. In this work, we have investigated the mechanisms by which
damage removal is accomplished during the onset of ES cell differentiation and report on an unexpected
induction and requirement of the proteasome activator PA28, normally associated with the immunoproteasome
and processing of antigens10.
Results
Differentiation-induced elimination of protein damage in ES cells requires active proteasomes. The decrease
in the levels of proteins carbonyls observed upon ES cell differentiation (Fig 1a)9 could be a result of dilution of
damage by an increased growth rate. This does not appear to be the case, however, since the number of doublings
per day decreased rather than increased during differentiation (Fig. 1b). Instead, damage elimination could be due
to a reduced rate of damage formation and/or an enhanced rate of damage removal (Fig. 1c). In order to approach
these possibilities, we first determined if differentiation resulted in a lowered cellular concentration of hydrogen
peroxide since protein carbonylation in biological samples is mainly formed by a metal catalysed oxidation that
involves a reaction with this oxidant2. However, there were no statistically significant differences in peroxide
levels between undifferentiated and differentiated cells (Fig 1d).
Focusing instead on damage elimination, we treated differentiating ES cells with the proteasome-specific
inhibitor epoxomicin (at a concentration causing a modest inhibition of activity) to test if proteasome activity
affects protein carbonyl levels. As shown in figure 1e–g, 20 nM epoxomicin led to a 67% inhibition of the
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proteasome (Fig. 1e) and an increased level of both ubiquitinated
(Fig. 1f) and carbonylated proteins (Fig. 1g). This elevation of carbo-
nylated proteins upon proteasome inhibition occurred without indu-
cing apoptosis (cleaved caspase-3 did not localize to the nucleus;
Supplementary Fig. S1), affecting viability (Supplementary Fig. S1),
or blocking differentiation (the undifferentiation marker SSEA-1 did
not remain localized to membrane as it would have been should the
cells have remained undifferentiated; Fig. 1h). These data suggest
that proteasome activity during early ES cell differentiation is
required to keep protein carbonyl levels at bay.
Differentiation of ES cells triggers production and assembly of
the PA28-20S proteasome complex. To elucidate the mechanism
behind the differentiation-induced boost in proteasome activity
demonstrated previously9, we quantified the absolute levels of
proteasome subunits. Since the protein carbonyls in ES cells are
mainly cytosolic9 we focused on the 20S core and the two known
cytosolic regulators of proteasome activity, 19S and PA28 (see
schematic representation in Fig. 2a)6,11. We found that the levels of
subunits of the 20S core (b5 and a mixture of a-subunits) and 19S
(Rpn7) were similar in undifferentiated and differentiated cells
(Fig. 2b). However, the levels of the PA28 subunits PA28a and b
and the 20Si immunoproteasome subunit b5i become markedly
elevated upon differentiation (Fig. 2b and immunocytochemical
detection of PA28a in Fig. 2c). Both the b5 and the b5i proteins
were found to be processed (around 23 kDa rather than 28–
30 kDa) suggesting that the b5i produced is incorporated into the
20S (Supplementary Fig. S2).
Real-time qPCR established that the increase in PA28a and b5i
levels is accompanied by a 4-fold elevation in PA28a transcripts
and a 15-fold induction of b5i mRNA during early differentiation
(Fig. 2d). In contrast, the transcripts of the 19S subunit Rpn7 and 20S
subunits a7 and b5 did not change (Fig. 2d). The cytokine TNFa12
and the transcription factor NF-kB13 are regulators of bi gene
expression and we found that TNFa expression was elevated upon
differentiation (Fig. 2e). In addition, IkBa, a known transcriptional
target of NF-kB14 was modestly induced upon differentiation sug-
gesting that the TNFa and, possibly, the NF-kB pathways are both
activated (though NF-kB activation may be a result of an active
TNFa pathway). In contrast, the levels of the third regulator of bi
and PA28a transcription, the immunomodulatory cytokine inter-
feron-c (IFN-c)15, were below the detection limit in both undiffer-
entiated and differentiated ES cells. In addition, mRNA levels of the
transcriptional target of IFN-c, the proteasome maturation protein
(POMP)16, was not elevated upon differentiation (Fig. 2e). Hence,
IFN-c is unlikely to be the upstream regulator for PA28a and b5i
induction during ES cell differentiation.
Using protocols optimizing for 20S interaction with either 19S or
PA2817 and non-denaturing gel electrophoresis, we demonstrated
that the PA28-20S complex is hardly detectable in undifferentiated
cells, but increases dramatically upon differentiation (Fig. 3a and 3b).
To confirm a physical interaction between PA28 and 20S, we immu-
noprecipitated 20S and found that PA28a co-precipitated with 20S in
differentiated ES cells (Fig. 3c). The levels of the 26S proteasome
displayed no major change upon differentiation (Fig. 3a and 3b;
see also detection of 19S under PA28-20S favouring conditions in
Supplementary figure S3). Moreover, as shown in figure 3d, the
activity of the PA28-20S complex is induced 5-fold upon early dif-
ferentiation (Supplementary figure S3 shows that 19S does not bind
20S during these conditions). In contrast, 26S activity does not
increase during differentiation and the substrate cleavage activity
of the PA28-20S complex in the cell extracts eventually surpasses
Figure 1 | Proteasome activity is essential for limiting protein damage during early differentiation of ES cells. (a) Levels of protein carbonyls during
differentiation of ES cells. The mean value of undifferentiated cells was set to 100% in each run and error bars represent SEM (n 5 3), p*** 5 8.8E-04
(one-way ANOVA followed by Tukey’s post hoc test, see Supplementary Fig. S5). (b) Doubling time of ES cells during differentiation. (c) Illustration of
different means by which protein carbonylation may be reduced; P denotes a native protein, PCRB the carbonylated form of the protein, and aa amino
acids. (d) Peroxide levels determined by DCFDA (left) and DHR (right) staining and FACS analysis. The value for undifferentiated cells was set to 1.0 and
error bars represent SEM (n 5 3). (e) Reduction of proteasome activity of ES cells during early differentiation by 20 nM epoxomicin. The mean
value of the undifferentiated cells was set to 100%, and error bars represent SD (n 5 2). (f) Ubiquitinated proteins and (g) protein carbonyls in ES cells
after 3 days of differentiation with or without epoxomicin as indicated (n$ 2). (h) SSEA-1 detection (green) andDAPI (blue) staining of undifferentiated
cells (left) and differentiated (3 days) cells with (right) and without (middle) epoxomicin treatment. (Images have been cropped; scale bar, 10 mm.)
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that of the 26S (Fig. 3d). Thus, the increase in proteasome activity
observed upon early differentiation (inset Fig. 3d) is predominantly
due to elevated levels of the PA28-20S.
PA28 is required for the reduction in protein damage elicited
by differentiation. To test if the PA28 activator is required for the
removal of carbonylated proteins triggered by differentiation, mi-
RNA was used to counteract PA28a accumulation in differentia-
ting cells. As shown in figure 4a, targeting PA28a abolished the
reduction in protein carbonyls upon differentiation while the mi-
RNA control (lacZ) did not. A similar increase in protein car-
bonyls upon reduced PA28a levels was observed in situ (Fig. 4b).
Treating undifferentiated ES cells with miRNA targeting PA28a had
no effect on protein carbonyl levels (Supplementary Fig. S4),
consistent with the observation that these cells have almost no
PA28a (Fig. 2b and 2c). We also used miRNA directed against
luciferase (Luc) as a control and found that in these experiments, a
25.5% (68.8) reduction in PA28a levels resulted in a 28.1% (66.3)
increase in the carbonyl load (Fig. 4c). Similarly, an alternative RNAi
methodology (siRNA directed against PA28a mRNA transfected
into differentiating ES cells with oligofectamine) generated a clear
inverse correlation between PA28a levels and carbonyl content in
these cells (R2 5 0.988; Fig. 4d).
To examine whether the change in carbonyl content uponmiRNA
treatment against PA28a is specifically due to a loss of PA28 rather
than 20Si or 26S, we analysed the effect of this treatment on b5i and
poly-ubiquitin levels. As shown in figure 4e, miRNA targeting
PA28a had no effect on b5i levels, excluding a concomitant down-
regulation of this 20Si subunit as PA28a levels are lowered. A
reduction in 19S (and thus 26S) would be expected to cause an
increase in the levels of poly-ubiquitinated protein; however, we
found thatmiRNA against PA28a lowered the levels of ubiquitinated
proteins (Fig. 4f). This apparent increase in 26S activity might be due
to competition between 19S and PA28 for 20S binding and in this
scenario a reduction in PA28 levels would result in elevated levels of
26S. Taken together, the data support that the elevated carbonyl
levels observed upon miRNA treatment against PA28a is the result
of reduced PA28 levels.
Discussion
The proteasome activator PA28 is produced in many cells upon
intensified immune responses, which often includes a replacement
of the regular 20S proteasomes with 20Si immunoproteasomes6,10.
Apart from being involved in antigen processing10, both PA28 and
20Simay have general protective functions related to oxidative stress.
Specifically, recent data point to PA28 participating in the degrada-
tion of misfolded proteins and the management of protein aggre-
gates18. Moreover, a link between PA28/20Si and protein quality
control is evidenced by the fact that PA28 overexpression in cultured
cardiomyocytes decreases protein carbonyl levels upon H2O2
Figure 2 | Subunits of PA28-20S(i) are elevated upon differentiation of ES cells. (a) Schematic presentation of the 20S and 20Si proteasomes and the two
cytosolic regulators, 19S and PA28. There are also hybrid proteasomes which contain both 19S and PA28 activator complexes38,39 which are not shown
here. (b) Representative Western blots of b5, a-subunits, a7 (20S core), Rpn7 (19S subunit), b5i (20Si subunit), PA28a, and PA28b (PA28 subunit) in
undifferentiated ES cells (0) and cells that have been differentiating for 3 and 5 days. (c) PA28a (red) and nuclei (blue) in undifferentiated and
differentiated ES cells, inset displays a zoomed in box of the PA28a image. (Scale bar, 25 mm.) (d) Relative levels of mRNA encoding 20S (b5 and a7), 19S
(Rpn7), 20Si (b5i; y-axis to the left), and PA28 (PA28a; y-axis to the right) subunits with HPRT as a reference gene. Values were normalized to that of
undifferentiated cells and error bars represent SEM (n$ 3), p***, 0.0000001 (one-way ANOVA followed by Tukey’s post hoc test, see Supplementary
Fig. S6). (e) Relative levels of mRNA encoding TNFa (green), IkBa (blue), and POMP (red) with HPRT as a reference gene. Values were normalized to
that of undifferentiated cells and error bars represent SEM (n$ 3); p***TNFa 5 0.000011 and p***IkBa 5 0.00018 (one-way ANOVA followed by Tukey’s
post hoc test, see Supplementary Fig. S7).
www.nature.com/scientificreports
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stress19, that knockdown of either PA28 or 20Si limits cellular adapta-
tion to H2O2 treatment20,21, and that 20Si is involved in the clearance
of protein aggregates upon IFN-c induced oxidative stress22. As
demonstrated herein, PA28 appears to be required also for the
clearance of carbonylated proteins upon the first signs of cell fate
specification. The potential in vivo relevance of these results are
underlined by the finding that PA28a, PA28b, and b5i are all
expressed during early mouse embryogenesis23.
The 26S proteasome and the ubiquitin-proteasome system (UPS)
have recently been implicated in the maintenance of the pluripotent
state24–26. It has been demonstrated that proteasome inhibition
induces differentiation24,25 but the quality of the resulting differen-
tiated cells regarding protein damage upon such inhibition was not
investigated. In addition, undifferentiated human ES cells (hESC)
were found to exhibit higher 26S proteasome activity compared to
differentiated cells24, consistent with our data showing a trend
towards a decline in 26S activity after the onset of differentiation.
Since the proteasome activity in the Vilchez et al., study24 was mea-
sured under conditions optimizing for the 26S proteasome (the
MgCl2 present in the assay excludes all PA28-dependent proteasome
activity17), it is not known if the reduced 26S activity in differentiated
cells was preceded by a transient elevated activity of the PA28-20S
proteasome. Thus, it would be interesting to test whether the onset
also of hESC differentiation includes a boost in PA28-dependent
proteasome activity.
PA28 knock-out mice are viable27 demonstrating that a failure to
properly boost PA28-20S activity upon ES cell differentiation is not
severely affecting the development or functionality of the embryo.
However, it could be speculated that a diminished ability to clear out
protein damage by the PA28-20S proteasome during early cell fate
specification could accelerate deterioration of metabolically active
tissues, such as neurons and muscles, in the adult and aging organ-
ism.Moreover, the involvement of the PA28-activated proteasome in
purging ES cells from oxidative protein damage suggests that this
may be accomplished without the need for ubiquitin tagging or ATP
and is in accord with data demonstrating that cells with compro-
mised ubiquitin-conjugating activity retain their ability to degrade
oxidized intracellular proteins at near normal rates28. A question of
interest is whether ectopic induction of the PA28 activator might
counteract the accumulation of oxidatively damaged and/or aggre-
gated proteins also in aging cells/tissues and whether this affects the
progression or timing of age-related protein conformational dis-
orders and the rate of aging itself.
Methods
ES cell line and culture conditions. The murine ES cell line R129,30 was used in all
experiments, except for proteasome activity and Western analysis upon epoxomicin
treatment and DHR FACS analysis which were done on E14.130,31. Several of the
experiments were done on both cell lines with similar results. Cells were cultured on
gelatin-coated plates in ES cell culture medium (Supplementary Table S1) as
previously described9.
Figure 3 | A functional proteasome activator PA28 is produced upon differentiation of ES cells. (a) Levels of mature PA28-20S(i) (left; detected using
antibodies against 20S a-subunits [green] and PA28a [red] on a blotted gel which had been run for 8.5 h; the middle blot displays the 20S channel alone)
and 26S (right; detected using antibodies against the 19S subunit Rpn7 [red] and 20S a-subunits [green] on a blotted gel which had been run for 12 h)
proteasomes. (b) Proteasome complexes PA28-20S(i) (red), 26S proteasome (blue), or 20S proteasome (grey) quantified from (a) and additional runs,
error bars represent SD (n $ 2); p* 5 0.013 and p** 5 0.0040 (one-way ANOVA followed by Tukey’s post hoc test, see Supplementary Fig. S8).
(c) Immunochemical detection of PA28a before and after 20S immunoprecipitation (IP) of 3-day differentiated ES cells; lanes from the left: (1) untreated
cell extract, (2) beads used to pre-clear extract, (3) 20S-IP beads (arrow indicates PA28a), followed by 4 lanes (4–7) of washes of the 20S-IP beads.
(d) Proteasome activity measured under conditions optimizing for either PA28-20S(i) (red), 26S proteasome (blue), or 20S proteasome (grey) assembly
and activity, error bars represent SD (n $ 2); p*day0-day3 5 0.037 and p*day0-day5 5 0.017 (one-way ANOVA followed by Tukey’s post hoc test, see
Supplementary Fig. S9). Inset shows the combined proteasome activity in pmol LLVY digested per mg protein and min, i.e. the sum of activity
measurements favouring PA28-20S(i), 26S proteasome, and 20S proteasome after 0, 3, and 5 days of differentiation.
www.nature.com/scientificreports
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Immunocytochemistry. The undifferentiated status of the ES cells was confirmed by
immunochemical staining of Oct-4, localized in the nucleus32, and SSEA-1, cell
surface-localized33; as previously described9. Immunocytochemical detection of
carbonyls was performed as described previously9. For detection of PA28a, the cells
were fixed in 4%PFA (15 min), permeabilized in 0.5%Triton X-100 (5 min), blocked
with 10% goat serum in PBS (40 min) at room temperature, and incubated with
rabbit anti-PA28a (15100; Abgent) overnight at 4uC, with goat anti-rabbit IgG A555
(15250; Molecular probes, Invitrogen) for 60 min, and DAPI (1 mg/mL) for 4 min at
room temperature.
ES cell differentiation and estimation of doubling time. Differentiation was
induced as described9, by removal of LIF and omission of continuous passage for 1, 2,
3 and 5 days. Time point ‘‘0’’ of differentiation refers to undifferentiated cells on a
plate of 80% confluency. This is when LIF is removed and passaging omitted to induce
differentiation and thus occurs at day 0 of differentiation (start). Doubling time
estimates of undifferentiated cells were based on the number of cells plated during
passage, the time until next passage, and the number of cells after trypsin treatment at
that time. For differentiated cells, the pellet weight at harvest was used as an
approximation of the relative number of cells, so that the increase in pellet weight over
time gave an estimation of the doubling rate.
Peroxide detection by DHR and DCFDA staining followed by FACS analysis.
Trypsin treated ES cells were incubated in DHR (5 mM for 10 min) or DCFDA
(20 mM for 30 min) and analysed using flow cytometry (FACS Aria, BD equipment
for DHR and FACSCalibur, BectonDickinson for DCFDA) with FITC filter settings,
gating on live cells.
Proteasome activity assays and proteasome inhibition. Cells were lysed in
PA28-20S or 26S lysis buffer (Supplementary Table S1). Cell debris was removed by
centrifugation and protein concentration was determined using the BCA Protein
Assay kit (Pierce). The chemotryptic activity was assayed by hydrolysis of the
fluorogenic peptide succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin
(suc-LLVY-AMC) (Bachem, Saffron Walden, U.K.). 20 mg total protein was
incubated with 200 mM suc-LLVY-AMC in PA28-20S or 26S optimizing buffer, or
20S buffer (see Supplementary Table S1) in a total volume of 100 ml; fluorescence was
read using 390 nm excitation and 460 nm emission filters with free AMC as standard
(Bachem). Lactacystin (30 mM, Enzo Life Sciences) inhibited the suc-LLVY-AMC
hydrolysis of the PA28-20S and 26S samples to 90.1% (63.8). Coomassie stained
SDS-PAGE gels were used to confirm equal protein levels in the assay. Proteasome
inhibition during ES cell differentiation was done by including 20 nM Epoxomicin
(Enzo Life Sciences) in the differentiation medium (without LIF).
Electrophoresis (SDS-PAGE and native PAGE) and western blot analysis. For
protein separation by SDS-PAGE, cells were lysed with a modified RIPA buffer
(Supplementary Table S1), cell debris was removed and protein concentration was
determined using the BCA Protein Assay kit (Pierce). Native PAGE samples were
extracted to optimize the 20S interaction to either PA28 or 19S as described above,
mixed with native gel loading buffer (Supplementary Table S1), and run on
non-denaturing PAGE (2.5% stacking and 4.5% separating gel)34. Samples were
prepared for SDS-PAGE as described (for detection of protein carbonyls9 and
absolute levels of specific proteins and ubiquitin35). Gel electrophoresis was followed
by blotting the proteins onto a PVDF (polyvinylidene difluoride) membrane
(Millipore). The following primary antibodies were used: rabbit pAb anti-2,4-
dinitrophenyl (Chemicon Oxyblot kit, Millipore), mouse mAb anti-ubiquitin (Santa
Cruz), mouse mAb anti-polyubiquitin (Abcam), rabbit pAb anti-b5, anti-Rpn7,
anti-PA28a, anti-PA28b andmousemAb anti-b5i, anti-a7, and anti 20S a subunits (a
mixture of antibodies against a1, a2, a3, a5, a6 and a7) (Enzo Life Sciences). IRDye
800CW-labelled or 680CW-labelled goat anti-mouse or anti-rabbit IgG antibodies
(LI-COR Biosciences) were used for detection and blots were analysed with the
Odyssey infrared imaging system and software (LI-COR Biosciences).
20S immunoprecipitation.Cells were lysed in PA28-20S lysis buffer (Supplementary
Table S1), cell debris was removed by centrifugation, and extracts were precleared
with protein A agarose beads (GE Healthcare), incubated with rabbit pAb anti-20S
subunits (Enzo Life sciences) and with beads. Beads were extensively washed with
Lysis buffer, and subjected to SDS-PAGE followed by Western analysis.
RNA extraction and quantitative (qPCR) analysis. Total RNA was extracted using
GenEluteTM Mammalian Total RNA Miniprep Kit from Sigma-Aldrich, and DNase
treated on-columnwith RNase-Free DNase Set (Qiagen) according tomanufacturer’s
instructions. cDNA was synthesized on 1 mg total RNA in First strand buffer
(Invitrogen), 50 nM random primers, 500 mMdNTPmixture and 5 mMDTT by 200
U SuperscriptTM III RT (Invitrogen) in 20 ml total volume; a reaction with no reverse
transcriptase was included for each sample. 1/100 of total synthesized cDNA were
analysed in triplicates by qPCR using iQTM SYBRH Green Supermix and the iQ5
detection system from Bio-Rad. For primer sequences, see Supplementary Table S2.
Figure 4 | PA28 is required for the clearance of protein carbonyls during differentiation of ES cells. (a) Levels of carbonylated proteins in
undifferentiated ES cells (0) and cells that have been differentiating for 5 days treated withmiRNA as indicated; lacZ constitutes themiRNAnon-targeting
control. Lanes from the same blot image have been cut together. (b) Protein carbonyl detection (red) and nuclei (purple) inmiRNA treated (as indicated)
ES cells after 3 days of differentiation. (Scale bar, 25 mm.) (c) Levels of protein carbonyls and PA28a in cells that have been differentiating 5 days with
miRNA treatment targeting PA28a, determined by SDS-PAGE followed by Western blotting and immunodetection, presented as percent difference
compared to themiRNAnon-targeting control (Luc). Themean value of control cells was set to 100%, error bars represent SEM (n5 3); pcarbonyls 5 0.012
(unpaired two-tailed t-tests of Luc vs PA28a targeting miRNA). (d) Inverse correlation between PA28a levels and protein carbonyls in undifferentiated
ES cells and cells that have been differentiating for 3 days while under siRNA treatment (non-targeting nucleotides and targeting PA28a) determined as
described in c), error bars represents SD (n $ 2). (e) Levels of b5i and (f) poly-ubiquitin in cells that have been differentiating 5 days with miRNA
treatment targeting luciferase (Luc) and PA28a determined as described in c). The mean value of control cells was set to 100%, error bars represent SEM
(n5 3); ppoly-ub 5 0.01019 (unpaired two-tailed t-tests of Luc vs PA28a targeting miRNA). Inset showsWestern-blot b5i (e) and poly-ubiquitin patterns
(f) of cells treated with miRNA targeting luciferase (1) and PA28a (2).
www.nature.com/scientificreports
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RNAi Inhibition of PA28a expression. miRNA treatment against PA28a was
performed using the BLOCK- iTTM Pol II miR RNAi expression vector kit with
pre-designed BLOCK-iTTM miR RNAi Select hairpins directed towards PA28a, lacZ,
and luciferase (the two latter being non-targeting controls) mRNA from Invitrogen
(see Supplementary Table S3). miRNA was cloned into the pcDNATM6.2-GW/miR
vector according to manufacturer’s instructions and correct insertion was confirmed
by sequencing. The vectors expressing miRNAwere introduced into undifferentiated
ES cells using a GenePulser (BioRad) with the following settings: 260 V, 500 mF,‘V,
in a 4 mm cuvette. After 24 h recovery, selection for the miRNA vector (7.5 mg/mL
blasticidin) was started in parallel to initiation of the differentiation protocol. Two
miRNA variants targeting PA28a were combined to inhibit PA28a expression (see
Supplementary Table S3). siRNA silencing was carried out as described36 using
Oligofectamine (Invitrogen) as transfection reagent. siRNA duplexes (see
Supplementary Table S4) were purchased from Dharmacon Research.
Statistical analysis.Comparisons between two groups were performedwith unpaired
t-tests assuming two-tailed distribution and equal variances and differences were
considered significant at p, 0.05. Statistical calculations for figures 1a, 2d, 2e, 3b, and
3d were done in R-2.15.2 (www.r-project.org)37 by one-way ANOVA followed by
Tukey’s post hoc test to compare groupmeans and the null hypothesis was rejected at
the 0.05 level.
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